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Abstract 1 
Inhaled corticosteroids (ICS) adherence is important for asthma management. Current evidence on the 2 
impact of ICS adherence on outcomes is mostly based on correlational analyses of between-person data. 3 
Although it is widely acknowledged that asthma outcomes fluctuate over time, evidence on predictors of 4 
within-person change is scarce. We aimed to quantify these fluctuations and the longitudinal relationships 5 
between ICS adherence and outcomes at both between- and within-person levels. 6 
 7 
A prospective cohort of persistent asthma patients in France and the United Kingdom (N = 847, age 6−40 8 
years) provided 3756 reports over up to 2 years via computer-assisted telephone interviews and text 9 
messages on ICS adherence, asthma control, reliever medication use, and exacerbations. We examined 10 
adherence−outcome relations via longitudinal models, controlling for confounders, including severity. 11 
 12 
Considerable within-person variability was found for exacerbations (91%), asthma control (59%), and 13 
reliever use (52%); 431 (11.5%) reports signalled exacerbations and 2046 (54.5%) poor control. At 14 
between-person level, patients with higher average adherence were more likely to report asthma control 15 
(OR=1.25 95%CI[1.06−1.47]) but not asthma exacerbations (OR=0.99 [0.87−1.12] or lower reliever use 16 
(b=-.0004 [-0.089−0.088]). At within-person level, higher-than-usual adherence was associated with 17 
higher concomitant reliever use (b=0.092 [0.053−0.131]) and lower subsequent reliever use (b=-0.047 [-18 
0.005− -0.088]); it was unrelated to asthma control (OR=0.93 [0.84−1.02]) or exacerbations (OR=1.04 19 
[0.94−1.16]).  20 
Patients maintaining high ICS adherence over time have better asthma control. Temporarily increasing 21 
ICS adherence tends to be simultaneous to higher reliever use and reduces reliever use later on. Causes 22 
of within-person variation in outcomes require more investigation. 23 
 24 
Take home message: 25 
Cohort study in routine care finds large variability in asthma outcomes over time. Patients with higher 26 
mean ICS adherence report better asthma control. ICS adherence and reliever use tend to increase at 27 
the same time and reduce use of relievers later on. 28 
Plain language summary: 29 
Taking inhaled corticosteroids as prescribed is important for managing asthma. For people who suffer 30 
from asthma, symptoms vary over time. We wanted to know whether differences between people in how 31 
they use their inhalers are related to how they experience symptoms, and also whether their symptoms 32 
change when they use their inhalers differently than usual. We found that people who keep taking their 33 
inhaled corticosteroids inhalers regularly as prescribed experience less symptoms in the long term. At 34 
times when they increase the use of their inhaled corticosteroids they also tend to use their reliever 35 
inhalers more, which does not have a large impact on symptoms or exacerbations but tends to result in 36 
less reliever use later on.  37 
Keywords: asthma; adherence to medications; inhaled corticosteroids; asthma control; asthma 38 
exacerbations; routine care 39 
40 
INTRODUCTION 1 
Inhaled corticosteroids (ICS) are a pillar of asthma management (1–3). Clinical guidelines recommend 2 
assessing and improving ICS adherence (1), yet current interventions achieve limited benefits (4). For 3 
interventions to be effective, they would need to rely on understanding adherence variations in routine 4 
care and their effects on outcomes both between persons (do patients who maintain on average higher 5 
adherence have better outcomes?) and within persons over time (do patients have better outcomes when 6 
they improve their adherence compared to their average level?). To date, research evidence has focused 7 
on the between-person level, mostly with cross-sectional designs, which have provided inconsistent 8 
results (5,6). As asthma is a variable condition, patients may experience substantial changes in 9 
symptoms and medication intake across time (7,8), therefore studying adherence as a dynamic time-10 
varying process is more appropriate (9). As cross-sectional studies are known to provide limited insight 11 
into causal links, a longitudinal examination of ICS adherence and its relationships with asthma-related 12 
outcomes would establish to what degree adherence is important both between and within persons over 13 
time. 14 
Within a European Commission-funded prospective cohort study in asthma (ASTRO-LAB) conducted in 15 
the United Kingdom (UK) and France (10), we investigated ICS adherence variations between and within 16 
persons and their relationships with three outcomes commonly used in asthma research: asthma control, 17 
reliever use, and asthma exacerbations. Asthma control and exacerbations are considered key endpoints 18 
of asthma management and capture distinct types of variation in clinical manifestations of asthma in 19 
response to treatment (11). Reliever use, while often used to indicate loss of control or moderate 20 
exacerbations (11,12), is also a self-management behaviour influenced by clinical factors as well as 21 
psychological factors (13,14), which varies across time and may impact on asthma control and 22 
exacerbations (15). We therefore also investigated between- and within-person variations of reliever use 23 
and their links with asthma control and exacerbations. We examined three research questions separately 24 
for each outcome. First, how was the variation in the asthma-related outcome distributed at between- and 25 
within-person levels (RQ1)? Second, were between-person differences in ICS adherence (and reliever 26 
use, if applicable) associated with the outcome (RQ2)? Third, were within-person current or prior 27 
fluctuations in ICS adherence and reliever use associated with variations in outcomes (i.e. at the same 1 
time or at the next measurement) (RQ3).  2 
METHODS 3 
Study design and participants 4 
The ASTRO-LAB study protocol, including sample size determination and regulatory approvals, was 5 
described elsewhere (10). Briefly, we enrolled French and British patients with persistent asthma, meeting 6 
the following criteria: 6-40 years old, ≥6 months of prescribed use of controller inhalers during a 12-month 7 
baseline period (ICS or long-acting beta-agonists [LABA] in monotherapy, or ICS and LABA in distinct 8 
inhalers or fixed-dose combinations); no chronic oral corticosteroids (OCS) use (≥15 consecutive days 3 9 
months before enrollment); no omalizumab use during the baseline period; no concomitant respiratory 10 
disease; and no asthma exacerbations 2 months before enrollment.  11 
Included participants were followed for 12-24 months via computer-assisted telephone interviews (‘regular 12 
interviews’) every 4 months, and monthly text messages. Adults and teenagers (12-40 years) and parents 13 
of children (6-11 years) reported on asthma control, adherence to controller medication, reliever use, and 14 
exacerbation occurrence. Monthly text messages inquired about new exacerbations since last contact, 15 
and positive answers triggered additional ‘post-exacerbation interviews’ (see Figure 1 for an overview). 16 
Primary care records, i.e. study-specific electronic records completed by participating general 17 
practitioners in France and THIN data (16) in the UK, were used to extract socio-demographic information 18 
(gender, age, country, primary care practice identifier) and compute asthma severity markers at baseline. 19 
For this analysis, we selected patients and reports with ICS inhalers prescribed for regular use, as 20 
detailed below. 21 
_______ 22 
INSERT Figure 1 ABOUT HERE  23 
_______ 24 
Measures 25 
Asthma exacerbations 26 
Exacerbations were defined as: OCS courses of ≥2 days, unscheduled primary care, or hospital contacts 1 
(emergency room visits and/or overnight hospitalizations), or death due to asthma. Interviewers described 2 
asthma exacerbations to patients as ‘asthma attacks’ (‘situations when asthma gets worse, for example 3 
when someone becomes too breathless to speak, and reliever/normal inhalers do not help enough’), 4 
assessed self-reported occurrence, identified dates of any exacerbations and ensured they were not 5 
previously recorded.  6 
Asthma control 7 
Asthma control was measured via the 5-item Asthma Control Questionnaire symptoms-only (ACQ; (17)) 8 
for adults and teenagers. ACQ-5 assesses presence and intensity of night symptoms, morning symptoms, 9 
activity limitations, shortness of breath, and weezing during the past week; mean scores <0.75 were 10 
coded as ‘well-controlled asthma’ (18). As the ACQ-5 is not available for children, we adapted for parent 11 
report the Royal College of Physicians three questions (RCP3Q; (19), which evaluate night symptoms, 12 
day symptoms (cough, weeze, chest tightness, breathlessness) and activity limitations over the past 13 
month; sum scores equal to 0 were considered ‘well-controlled asthma’ (20). 14 
Reliever use 15 
To facilitate recall during the interview conversations, we developed and pilot-tested two questions on 16 
reliever use (short-acting beta agonists and anticholinergics). We asked how often relievers were used 17 
over the past 4 weeks (‘every day’, ‘almost every day’, ‘once or twice every week’ and ‘less than once a 18 
week’), then more details on the number of inhalations and times which were used to estimate the daily 19 
average number of inhalations (Supplementary Online Material 1; SOM1); values were winsorised (range 20 
0 – 6) for model convergence.  21 
ICS adherence 22 
We developed and validated the Medication Intake Survey - Asthma (MIS-A), a new instrument for 23 
telephone interviews, which assesses adherence separately for each controller inhaler based on self-24 
reported prescription start date, daily dosage recommendations, and 6 questions on controller use over 25 
increasing time periods (1 day to 4 months); percentages of medication used versus prescribed are 26 
calculated first for each question and subsequently as composite scores (21). In the present analysis, we 1 
used 1-week composite scores based on: (Q1) inhalations used the day before; (Q2) days on which no 2 
inhalations were used in the past 7 days; (Q3) days on which all prescribed inhalations were used in the 3 
past 7 days. We computed scores for each inhaler and then averaged across inhalers for reports when 4 
patients used >1 ICS. 5 
For asthma control, reliever use and ICS adherence, reporting was required for the period immediately 6 
prior to the interview (regular reports in regular interviews) or before the exacerbation (pre-exacerbation 7 
reports, in regular or post-exacerbation interviews). 8 
Patient characteristics 9 
Asthma severity at baseline was: 1) the number of OCs courses prescribed 12 months before the first 10 
interview, from primary care records, and 2) the ICS daily dose prescribed self-reported at first interview 11 
(beclometasone equivalent doses (22)). Type of ICS-based treatment was grouped into 3 categories: ICS 12 
in fixed dose combination with LABA (FDC; reference group), single ICS inhaler (‘ICS only’) and a third 13 
category (‘ICS plus’) for reports of ≥1 ICS (single or FDC) and a LABA (in a separate inhaler) and/or 14 
leukotriene antagonists (LTRA). Gender, country (UK or France), and age at enrollment coded in three 15 
categories -adults (18-40, reference group), teenagers (12-17) and children (6-11)- were extracted from 16 
primary care records.  17 
Analysis 18 
Data were analysed using R (23). We identified variables that predicted missing interviews (22.28% 19 
planned regular interviews were skipped and 33.52% of SMS texts did not receive a reply), and included 20 
them as predictors in the main models. Missing data in recorded reports were rare due to compulsory 21 
completion rules, and replaced by mode, median, or closest value (SOM2). To isolate the effects of the 22 
implementation stage of ICS adherence (24), i.e. the extent to which patients take the doses prescribed 23 
while on treatment, we censored the follow-up of patients (i.e. we kept only their previous reports in the 24 
dataset) when they had a report with no daily ICS prescribed (no ICS prescribed at all, ICS ended 25 
recently without any other ongoing/started ICS, ICS prescribed as needed, or only daily LABA prescribed) 1 
or in which they reported being prescribed other asthma controllers (e.g., tiotropium).  2 
Continuous time-varying predictors (adherence and reliever use) were decomposed into three variables 3 
to distinguish between-person effects and simultaneous and sequential within-person effects. Average 4 
adherence/use was calculated as the mean score for each patient across all reports (one score per 5 
patient) and used for examining whether differences in adherence/use between patients predict 6 
outcomes. Current fluctuation was the difference between patient’s average adherence/use and the 7 
score in a given report (multiple scores per patient) and helped examine whether changes in 8 
adherence/use within patients are associated with concomitant changes in outcome (i.e. measured in the 9 
same report). Prior fluctuation was computed as lagged variable, i.e. the difference between patient’ 10 
average and the score in their previous report (25), usually 4 months earlier (thus, also multiple scores 11 
per patient); similar to ‘current fluctuation’, this variable aimed to examine whether changes in 12 
adherence/use predict outcomes measured in the subsequent report.  13 
Descriptive statistics were calculated for patient characteristics, adherence and outcomes, and bivariate 14 
relations between adherence variables were examined between and within-person. We followed 15 
established procedures for hierarchical longitudinal modelling (25). Two-level longitudinal mixed models 16 
(LMM; reports within patients) were built separately for asthma control and exacerbation occurrence 17 
(logistic models), and reliever use (linear models). We conducted visual data exploration fitting non-18 
parametric lowess functions (see SOM2), which supported the appropriateness of linear modelling. First, 19 
unconditional means models were built to assess the proportion of variance at different levels via 20 
Variance Partition Coefficients (VPC) for logistic models, or intra-class correlation coefficients (ICC) for 21 
linear models (RQ1). A cut-off of .05 indicated substantial variance (26). Practice was initially modeled as 22 
third level, and excluded for not meeting this criterion. Several variance-covariance structures of residuals 23 
(compound symmetry, first-order autoregressive, general correlation matrix) were compared for the linear 24 
models and the best fitting selected; logistic models specified unstructured covariance. Next, 25 
unconditional growth models were tested, with time modelled as days since the first interview per patient 26 
(random and fixed); models were compared and selected based on fit and parsimony. Conditional growth 27 
models added covariates (including reliever use for asthma control and exacerbation models) and 1 
adherence predictors (personal average, current effect, lagged effect). Residuals of the full models were 2 
examined for normality.  3 
Exploratory analyses were also performed to examine possible moderators of adherence-outcomes 4 
relationships: age, type of ICS, country, and severity. Sensitivity analyses were performed with 1-month 5 
adherence scores (SOM3). 6 
RESULTS 7 
Sample characteristics 8 
Of 4647 reports from 934 patients collected between May 2013 and January 2016, 3756 reports (847 9 
patients) were included (see flowchart in Figure 2). There were 1-13 reports per patient (median = 4, 10 
inter-quartile range(IQR) = 4); resulting in mean (SD) follow-up time of 406 (249) days, and maximum 758 11 
days. Patients were predominantly French (80.4%), with good gender and age representation (47.6% 12 
female; 56.6% adults). Of 3756 CATI reports, 1929 (51.4%) were about FDC, 785 (20.9%) about ICS in 13 
single inhalers, and 1042 (27.7%) were prescribed LABA and/or LTRA in addition to ICS. Exacerbations 14 
were reported by 246 patients in 433 (11.5%) reports. Median 1-week adherence was 85.71% (IQR = 15 
50%). Patients indicated ICS adherence above 80% in 55.88% reports. Uncontrolled asthma was 16 
reported by 683 patients in 2046 (54.5%) reports. Median reliever use was 0.18 inhalations per day 17 
(range 0 to 6). Sample characteristics are reported in Table 1. 18 
_______ 19 




INSERT Table 1 ABOUT HERE 24 
_______ 1 
Longitudinal associations between ICS adherence and asthma outcomes 2 
Table 2 presents results for the composite 1-week adherence score (similar results with 1-month scores 3 
available in SOM3). Most variation in outcomes was present at within-person level; the proportion of 4 
variation between-person was 41% for asthma control, 9% for exacerbations, and 48% for reliever use.  5 
Asthma control. Patients with higher average ICS adherence were more likely to report controlled asthma 6 
(OR 1.25 [95% CI, 1.06-1.47] per 1 SD=26%). At within-person level, current and prior fluctuations in ICS 7 
adherence had no significant association with asthma control (OR 0.93 [95% CI, 0.84-1.02] and 1.05 8 
[95% CI, 0.95-1.15]). Controlled asthma was also more likely in patients who on average used less 9 
relievers (OR 0.30 [95% CI, 0.24-0.37] per 1 SD=1.23 times/day). Current increases in reliever use were 10 
associated with decreased likelihood of controlled asthma (OR 0.50 [95% CI, 0.43-0.58] per 1 SD=1 11 
time/day); prior fluctuations had no effects on asthma control (OR 1.04 [95% CI, 0.94-1.16]). Of note, 12 
when reliever use variables were excluded from the model (see SOM3), current fluctuations in ICS 13 
adherence were weakly associated with asthma control; since ICS adherence and reliever use were 14 
associated and both reacted to changes in symptoms, this suggests that common variance in asthma 15 
control was explained here by fluctuations in reliever use.Well-controlled asthma was less likely for 16 
children compared to adults, for patients in the UK compared to France, for patients taking ICS with add-17 
on medication compared to FDC, and for patients with higher dose of ICS at baseline. In exploratory 18 
analyses, we identified age as a moderator for the effect of average ICS adherence on asthma control, 19 
which was weaker for children and adolescents (see SOM3). Asthma control increased during the study. 20 
Exacerbations. Average ICS adherence scores and prior or simultaneous fluctuations were not 21 
associated with exacerbation occurrence (OR 0.99 [95% CI, 0.87-1.12], OR 1.04 [95% CI, 0.94-1.16] and 22 
0.99 [95% CI, 0.89-1.11]). Patients with higher average reliever use were more likely to report an 23 
exacerbation (OR 1.46 [95% CI, 1.30-1.63] per 1 SD=1.23 times/day); current and prior fluctuations in 24 
reliever use were unrelated to exacerbations (OR 1.08 [95% CI, 0.98-1.19] and 1.00 [95% CI, 0.91-1.10]). 25 
Exacerbations were more likely to occur earlier in the study, in children, women, in France, for patients 26 
taking add-on medication, and with higher asthma severity. 27 
Reliever use. Average ICS adherence scores were unrelated to reliever use (b=-0.0004, [95% CI, -0.089-1 
0.088]). When patients increased their ICS adherence (current fluctuation) they also reported higher 2 
reliever use simultaneously (b=0.092, [95% CI, 0.053-0.131] per 1 SD=20%), and lower reliever use in 3 
the next interview (prior fluctuation; b=-0.047, [95% CI, -0.005- -0.088] per 1 SD=20%). Reliever use was 4 
higher for British patients, and those with higher asthma severity. 5 
_______ 6 
INSERT Table 2 ABOUT HERE 7 
_______ 8 
DISCUSSION 9 
This study presents evidence on the long-term role of ICS adherence in asthma routine care, based on 10 
detailed patient-reported data collected by trained interviewers via computer-assisted telephone 11 
interviews from participants aged 6 to 40 years in two European countries. Hierarchical longitudinal 12 
models disentangled effects of both average (between-person) levels and within-person fluctuations of 13 
ICS adherence on asthma control, exacerbations, and reliever use. The role of reliever use was also 14 
examined using the same approach. 15 
Regarding Research Question 1, we found considerable variation in asthma outcomes and reliever use 16 
due to within-person fluctuations (91% of the chances of reporting exacerbations; 59% of asthma control; 17 
52% of reliever use) rather than between-person differences. These fluctuations can only be explained by 18 
factors changing within patients over time and not by stable differences between patients. This indicates 19 
that commonly-used between-person designs are not suited to explaining the full variation in asthma 20 
outcomes, and highlights the need to also focus on within-person variation. Previous findings from the 21 
Astrolab cohort (21) indicate substantial within-person variability in ICS adherence scores as well (41-22 
71%). We recommend using hierarchical modeling more broadly in respiratory research, especially given 23 
that longitudinal data are increasingly collected in routine care via digital technologies (27). These results 24 
also highlight the importance for clinical practice to assess not only average levels of medication use and 25 
outcomes across time, but also how these change between consultations. Moreover, interventions 26 
would need to identify and target personal and context factors that changed during or before this period 1 
and possibly caused changes in the patient’s behaviours and health status. 2 
Separating effects of long-term average levels from temporary fluctuations in medication use allowed us 3 
to answer two related but distinct questions regarding ICS adherence and reliever use. Regarding 4 
Research Question 2, we found that between-person differences in ICS adherence were associated with 5 
better asthma control (patients who were on average 26% more adherent to ICS were 25% more likely to 6 
report controlled asthma), but not exacerbations or reliever use. These results can be interpreted 7 
following the Asthma Care logic Model (ACM; (28): ICS adherence is temporally more proximal to asthma 8 
control than exacerbations, and patient behaviours during symptom aggravation, including reliever use, 9 
may have independent contributions to exacerbation occurrence and severity.  10 
Regarding Research Question 3 focusing on within-person fluctuations in ICS adherence and reliever use 11 
both prior and concurrent to a given report, we found that at times when patients increased their ICS 12 
temporarily they tended to increase simultaneously their reliever use, and to report less reliever use 13 
following these times (with an increase of 20% in ICS adherence corresponding to using relievers 1 time 14 
more than usual in 11 days in the same period and using them 1 time in 21 days less than average in the 15 
next report). Temporary fluctuations in ICS adherence were unrelated to asthma control or exacerbations. 16 
Prior studies have mostly reported a protective effect of ICS adherence on outcomes, yet some found 17 
either positive or no associations (5,6). Increasing ICS adherence in response to worsening symptoms 18 
has been proposed as an explanation for these paradoxical results (29,30). Our findings are consistent 19 
with this possibility, and start building a more nuanced picture of the dynamic interplay between asthma 20 
medication use and health status, which is undetectable with a between-person design. Importantly, they 21 
concur with recent calls for reconsidering the role of relievers (short-acting beta agonists) in asthma 22 
management following concerns of preferential use in place of controller inhalers, which may mask 23 
underlying inflammation by providing only symptom relief; in contrast, improving ICS adherence (in 24 
response to symptom aggravation or proactively as part of a self-management plan) reduces 25 
inflammation and therefore future need for symptom relief (31). 26 
Several findings on other predictors of asthma outcomes are important to highlight. Men reported less 1 
exacerbations, consistent with recent findings on large medical records data in the UK (32). There were 2 
less exacerbations and more reliever use reported in the UK, possibly explained by better implementation 3 
of self-management support in primary care (33), which includes increasing controller and reliever use as 4 
a first step before OCs use (1). Patients who had at least one ICS prescribed (single or FDC) and a LABA 5 
and/or LTRA reported less control and more exacerbations compared to FDC, consistent with clinical 6 
recommendations for stepwise asthma treatment (1). All associations with the two severity markers were 7 
in the expected direction, except a nonsignificant effect of number of OC courses during the baseline year 8 
on asthma control. The alignment of these results with previous research supports the validity of the main 9 
findings. 10 
Our findings need to be interpreted in light of several limitations. First, given the prospective cohort 11 
design, we were only able to examine the role of average levels of adherence and fluctuations from 12 
average in usual care. Our results therefore do not exclude the possibility that a systematic effort to raise 13 
average levels of adherence long term may well have a positive effect on asthma outcomes. Second, we 14 
found that, as the study progressed, patients reported better outcomes, partly driven by selective attrition 15 
of participants with worse asthma control (see missing value analyses in SOM2); moreover, differences in 16 
proxy versus self-report and asthma control measures may have contributed to more reports of 17 
uncontrolled asthma and exacerbations in children. Controlling for time (days since first interview) and 18 
age in our models adjusted for these sources of bias. Third, we grouped treatment regimens based on 19 
commonly-used categories and did not consider possible variations in pharmacokinetic and 20 
pharmacodynamic profiles of ICS formulations (34), and interactions with LABA in FDC (35); we 21 
encourage replications of this approach on specific medications. Fourth, adherence was measured by 22 
self-report. The interview questions were carefully worded to improve recall and reduce social desirability, 23 
and they were previously validated against objective measures (21). Nevertheless, there are limitations 24 
related to the use of self-reports over 4-month time intervals when studying continuous processes. In the 25 
not-too-distant future, similar studies could be conducted with user-friendly electronic monitors for both 26 
adherence and outcomes (e.g., asthma control). Finally, a 4-month lag between measurements was most 27 
feasible given the study context, yet it can only capture medium-term variation. Clinical outcomes have 28 
been shown to improve within weeks from starting ICS, and return to baseline levels within weeks after 1 
treatment cessation or reduction (36–38). Variation in medication use for different time intervals, lags and 2 
data sources need to be further studied, as the feasibility of data collection will increase with the 3 
development of digital technologies. 4 
This study demonstrated a novel approach to examining ICS adherence in asthma routine care. By 5 
separating between- and within-person variation, we captured a potentially protective role of ICS 6 
adherence for asthma control long term, and an interplay between ICS and reliever use short term, which 7 
deserves further investigation. These findings suggest three recommendations for clinicians aiming to 8 
help patients improve their asthma management. First, clinicians should expect that medication use and 9 
health status fluctuate over time, and routinely assess these in a factual, non-judgmental manner, for 10 
example using the questions in Table 3 (adapted from Astrolab interviews). Second, they should clarify 11 
how patients use both controllers and relievers in relation to symptoms and agree on asthma action 12 
plans. And third, they should support patients to work towards high average levels of adherence to the 13 
agreed ICS daily dosage for long-term control.  14 
_______ 15 
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Table 1. Sample characteristics - descriptive statistics 1 
Characteristic Statistic 
Patient level (N=847) 
 
Country (% French) 681 (80.4)  
Gender (% women) 403 (47.6)  
Age (% adults) 479 (56.6) 
        (% children) 206 (24.3) 
        (% teenagers) 162 (19.1) 
Baseline severity (number of OC courses; median[range]) 0.00 [0.00, 7.00] 
Baseline severity (number of ICS and LABA canisters; median[range]) 12.00 [2.00, 60.00] 
Baseline severity (ICS daily dose at first interview; median[range]) 500.00 [100.00, 10000.00] 
Report level (n=3756) 
 
Treatment type (% FDC) 1929 (51.4)  
             (% ICS single inhaler) 785 (20.9)  
             (% ICS plus LABA/LTRA) 1042(27.7) 
Asthma control (% uncontrolled) 2046 (54.5)  
Exacerbations (% occurrence) 433 (11.5)  
Time - days since first CATI (mean(SD)) 261.19 (220.16) 
Reliever use (median[range]) 0.18 [0.00, 6.00] 
1-month adherence – composite (median[range]) 85.71 [0.00, 100.00] 
1-week adherence - composite (median[range]) 85.71 [0.00, 100.00] 
1-day taking adherence (median[range]) 100.00 [0.00, 1250.00] 
1-week therapeutic coverage (median[range]) 100.00 [0.00, 100.00] 
1-week correct dosing (median[range]) 85.71 [0.00, 100.00] 
1-month therapeutic coverage (median[range]) 92.86 [0.00, 100.00] 
4-month drug holidays (median[range]) 100.00 [0.00, 100.00] 
Note: Abbreviations: OC, oral corticosteroids; ICS, inhaled corticosteroids; LABA, long-acting beta agonists; LTRA, 1 
leukotriene antagonists; FDC, fixed dose combination; SD, standard deviation. 2 
 3 
Table 2. Multilevel models of asthma control, AE (logistic) and reliever use (linear) 
 
 Dependent variable:   
Asthma control (OR[CI]) Exacerbation occurrence (OR[CI]) Reliever use (b(SE)) 
Intercept 0.78@ [ 0.59 – 1.04 ]  0.15*** [ 0.12 - 0.19 ]  0.819*** (0.079) 
Time (days since first CATI) a 1.31*** [ 1.16 - 1.48 ]  0.58*** [ 0.5 - 0.67 ]  -0.109*** (0.027) 
Gender (male) 1.24 [ 0.89 - 1.71 ] 0.70** [ 0.54 - 0.90 ] -0.017 (0.091) 
Age (child) 0.45*** [ 0.30 - 0.68 ]  1.68** [ 1.23 - 2.29 ]  -0.074 (0.112) 
Age (teenager) 0.81 [ 0.52 - 1.25 ] 0.98 [ 0.68 - 1.43 ] -0.180 (0.120) 
Country (UK) 0.87 [ 0.52 - 1.44 ] 0.56* [ 0.35 - 0.90 ]  0.441*** (0.136) 
Treatment type (ICS only#) 1.26 [ 0.85 – 1.86 ] 0.85 [ 0.60 - 1.21 ] 0.021 (0.102) 
Treatment type (ICS plus#) 0.71* [ 0.51 – 0.99 ]  1.54** [ 1.18 – 2.02 ]  0.038 (0.086) 
Baseline severity (number of OC courses) a 1.15@ [ 0.98 - 1.34 ] 1.27*** [ 1.14 - 1.41 ]  0.117** (0.045) 
Baseline severity (ICS daily dose at first 
interview) a 
0.61*** [ 0.50 - 0.74 ]  1.17** [ 1.05 - 1.31 ] 0.109* (0.046) 
1-week ICS adherence    
Average adherence a,b 1.25** [ 1.06 - 1.47 ]  0.99 [ 0.87 - 1.12 ] -0.0004 (0.045) 
Current fluctuation a 0.93 [ 0.84 - 1.02 ] 1.04 [ 0.94 - 1.16 ] 0.092*** (0.020) 
Prior fluctuation a 1.05 [ 0.95 - 1.15 ] 0.99[ 0.89 - 1.11 ] -0.047* (0.021) 
Reliever use    
Average use a,b 0.30*** [ 0.24 - 0.37 ]  1.46*** [ 1.30 - 1.63 ]  
 
Current fluctuation a 0.50*** [ 0.43 - 0.58 ]  1.08 [ 0.98 - 1.19 ] 
 
Prior fluctuation a 1.04 [ 0.94 - 1.16 ] 1.00 [ 0.91 - 1.10 ] 
 
VPC (logistic); ICC(linear) 0.4075 0.0891 0.4765 
Observations 2,909 2,909 2,909 
Log Likelihood -1,618.598 -1,104.696 -4,793.214 
AIC 3,271.195 2,243.392 9,622.429 
BIC 3,372.780 2,344.977 9,729.989 
Notes: @ p<.1; * p<.05; ** p<.01; *** p<.001; a variable standardized before inclusion into regression model to facilitate interpretation and model convergence 
(z-scores); ,b Average denotes individual mean across the follow-up period; # Reference group = ICS with LABA in fixed dose combination, ICS only = single ICS 
inhaler, and ICS plus = at least one ICS and a LABA in separate inhaler and/or LTRA; Abbreviations: OR, odds ratio; CI, confidence intervals; b, b coefficient; SE, 
standard error; UK, United Kingdom; ICS, inhaled corticosteroids; OC, oral corticosteroids; LABA, long-acting beta agonists; LTRA, leukotriene antagonists; VPC, 
Variance Partition Coefficient; ICC, Intra-class correlation; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion.  
Table 3. Example questions for assessing asthma control, ICS adherence and reliever use 
Variable Question examples  
In the last month,  
Asthma control 
(RCP3Q; 19) 
- Have you had difficulty sleeping because of your asthma symptoms 
(including cough)? 
- Have you had your usual asthma symptoms during the day (cough, 
wheeze, chest tightness or breathlessness)? 
- Has your asthma interfered with your usual activities (e.g. housework, 
work, school, etc.) 
Never/rarely/every week/ every day 
(answers ‘rarely’ or more for at least one question indicate uncontrolled 
asthma) 
ICS adherence - On how many days did you not use your ICS inhaler at all, for example 
because you forgot or did not want to use it? 
(number of days x 100 / 28 = % ICS adherence)  
Reliever use - How often have you usually taken [your reliever inhaler]? 
Every day/ almost every day/ once or twice every week / less than once a week 
- How many puffs how many times per day/week, on average? 






Figure 1. Example illustration of study timeline and data collection schedule – hypothetical example for a 
participant with 7 regular computer-assisted telephone interviews and two interviews after asthma 
exacerbations were identified by text messages (SMSs) at month 2 (M2) and 21 (M21). Primary care 
records were used at baseline to extract patient socio-demographic and medical history variables. 
 
_______ 
Figure 1 provided in separate file 
_______ 
 
Figure 2. Flowchart for the selection of interview reports and patients meeting analysis criteria (Note: 
reports were censored, therefore part of the patients with excluded reports remained in the sample; 
abbreviation: LABA, long-acting beta agonists). 
 
_______ 
Figure 2 provided in separate file 
_______ 
 
